Two other randomized clinical trials involving recombinant G-CSF in severe sepsis and community acquired pneumonia demonstrated an increase in total leukocyte counts in patients receiving the experimental therapy; however, there were no significant improvements in 28-day mortality [90,91]. This evidence concerns the gene CSF3 and Sepsis.